AbbVie to Present at the Morgan Stanley Healthcare Conference
Last abbvie, inc earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
NORTH CHICAGO, Ill., Aug. 27, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10, 2019. Richard A. Gonzalez, chairman and chief executive officer, will present at 10:10 a.m. Central time.A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees a
[Read more]
| Impact snapshot | Event time: | ABBV | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ABBV alerts
ABBV alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie, Inc news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Gordon Pape’s mailbag: Reducing risk, deciphering equity analyst targets and other investing dilemmas [Toronto Globe and Mail (Ontario, Canada)]Toronto Globe and Mail
- AbbVie Inc (NYSE: ABBV) had its price target raised by analysts at Mizuho from $101.00 to $110.00. They now have a "buy" rating on the stock.MarketBeat
- Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegolPR Newswire
- AbbVie Inc (NYSE: ABBV) had its price target raised by analysts at Royal Bank of Canada from $102.00 to $125.00. They now have an "outperform" rating on the stock.MarketBeat
- Sosei, AbbVie sign drug discovery deal worth up to $1 billion [Reuters]Reuters
- More
ABBV
SEC Filings
- 7/2/20 - Form 4
- 7/2/20 - Form 4
- 7/2/20 - Form 4
- ABBV's page on the SEC website
- More